Aberrant TGF-β signaling has been observed in a preclinical prostate cancer model, in which the tumor suppressor PTEN is silenced specifically in the prostate, leading to premalignant alterations of the prostate epithelium. The gene discussed is TGFB1; the disease is prostate carcinoma.